Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin Diseases AND Angioedema AND Urticaria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Skin Diseases AND Angioedema AND Urticaria. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-004254-25 Sponsor Protocol Number: CIGE025EDE16 Start Date*: 2012-05-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, 28-week treatment study with an 8 week follow-up period to investigate the impact of subcutaneous Omalizumab on quality of life measures...
    Medical condition: moderate to severe chronic spontaneous urticaria with angioedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002308-15 Sponsor Protocol Number: P160913 Start Date*: 2018-11-09
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: COrticosteroids in acUte uRticAria in emerGency dEpartment
    Medical condition: Adults patients with isolated acute urticaria presenting to the emergency department
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10001106 Acute urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022864-12 Sponsor Protocol Number: AA-10-1.01 Start Date*: 2011-04-20
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab ...
    Medical condition: Disease to be investigated: 12 patients with severe chronic urticaria (CU) with or without angioedema which continously need medical treatment As a control: 6 patients with atopy syndrome consisti...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009159 Chronic urticaria LLT
    12.1 10021247 Idiopathic urticaria LLT
    12.1 10003639 Atopic dermatitis LLT
    12.1 10031673 Other atopic dermatitis and related conditions LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000169-17 Sponsor Protocol Number: D3259C00001 Start Date*: 2020-12-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b Multinational, Randomized, Double-blind, Parallel Group, 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Chronic Spontaneo...
    Medical condition: chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10046735 Urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022785-27 Sponsor Protocol Number: Q4882g Start Date*: Information not available in EudraCT
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO Evaluate the efficacy, RESPONSE DURATION and safety OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDI...
    Medical condition: CHRONIC IDIOPATHIC URTICARIA (CIU)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10021247 Idiopathic urticaria LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed) DK (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022782-99 Sponsor Protocol Number: Q4881g Start Date*: Information not available in EudraCT
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO Evaluate the efficacy and safety OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (...
    Medical condition: CHRONIC IDIOPATHIC URTICARIA (CIU)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10021247 Idiopathic urticaria LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed) DK (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005424-97 Sponsor Protocol Number: CIGE025EFR02 Start Date*: 2015-01-28
    Sponsor Name:NOVARTIS PHARMA SAS
    Full Title: A phase IV, multicenter, single-arm and open-label study to explore the impact on quality of life of omalizumab (Xolair®) in patients with chronic spontaneous urticaria (CSU) who remain symptomatic...
    Medical condition: chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004216-31 Sponsor Protocol Number: CIGE025E2201 Start Date*: 2012-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multi-centre, randomized, double blind, placebo-controlled study to determine the mode of action of omalizumab in patients with chronic idiopathic urticaria (CIU) who remain symptomatic...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022784-35 Sponsor Protocol Number: Q4883g Start Date*: 2011-08-08
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY STUDY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE TREATME...
    Medical condition: CHRONIC IDIOPATHIC URTICARIA (CIU)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10021247 Idiopathic urticaria LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023057-11 Sponsor Protocol Number: DC02/RUP/3/09 Start Date*: 2011-02-09
    Sponsor Name:J. Uriach y Compañía, S.A.
    Full Title: Efficacy and safety of rupatadine solution in the treatment of Chronic Spontaneous Urticaria (CSU) in paediatric patients (2-11 years old).
    Medical condition: Treatment of Chronic Spontaneous Urticaria (CSU) in paediatric patients (2-11 years old).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003168-25 Sponsor Protocol Number: ONCE-AID1.0 Start Date*: 2023-02-28
    Sponsor Name:Academisch Medisch Centrum
    Full Title: Oral ONCE Daily prophylaxis with PHA-022121 in Patients with Acquired C1-Inhibitor Deficiency
    Medical condition: Acquired angioedema due to C1-inhibitor deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.0 10040785 - Skin and subcutaneous tissue disorders 10081035 Acquired C1 inhibitor deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006413-11 Sponsor Protocol Number: CDX0159-06 Start Date*: 2022-07-27
    Sponsor Name:Celldex Therapeutics
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Spontaneous Urticaria
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Ongoing) PL (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003756-33 Sponsor Protocol Number: EFC16720 Start Date*: 2021-03-25
    Sponsor Name:Sanofi-aventis recherche et développement
    Full Title: A randomized, double-blind, placebo-controlled, multi-center, parallel-group study of dupilumab in patients with chronic inducible cold urticaria who remain symptomatic despite the use of H1-antihi...
    Medical condition: Cold Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006447-95 Sponsor Protocol Number: CDX0159-07 Start Date*: 2022-09-09
    Sponsor Name:Celldex Therapeutics
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Inducible Urticaria
    Medical condition: Chronic Inducible Urticaria
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004858 10012499 Dermatographic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004458-41 Sponsor Protocol Number: D-001-01 Start Date*: 2018-10-04
    Sponsor Name:Charité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult pa...
    Medical condition: chronic spontaneous urticaria despite H1-antihistamine treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000181-21 Sponsor Protocol Number: BUCSU Start Date*: 2014-07-02
    Sponsor Name:Charite - Universitätsmedizin Berlin
    Full Title: Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001262-25 Sponsor Protocol Number: D-001-02 Start Date*: 2018-11-21
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (an...
    Medical condition: Cholinergic urticaria despite H1-antihistamine treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003775-19 Sponsor Protocol Number: EFC16461 Start Date*: 2020-09-23
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Master protocol of three randomized, double-blind, placebo-controlled, multi center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic ...
    Medical condition: Chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) GB (GB - no longer in EU/EEA) ES (Completed) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2021-001796-17 Sponsor Protocol Number: TV45779-IMB-30086 Start Date*: 2021-11-30
    Sponsor Name:Teva Pharmaceuticals, Inc.
    Full Title: A Multinational, Multicenter, Randomized, Double Blind Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of TEV-45779 Compared to Omalizum...
    Medical condition: Chronic Idiopathic Urticaria/Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020197 Hives LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) PL (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002581-51 Sponsor Protocol Number: AK002-006 Start Date*: 2018-01-10
    Sponsor Name:Allakos Inc.
    Full Title: An Open-Label, Pilot Study to Assess the Efficacy and Safety Of AK002 (Siglec-8) in Patients with Antihistamine-Resistant Chronic Urticaria
    Medical condition: Patients with different types of chronic urticaria resistant to standard dose antihistamines
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:34:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA